- Home
- FIGS vs AKBA Comparison
FIGS vs AKBA Comparison
Compare FIGS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- AKBA
- Stock Information
- Founded
- FIGS 2013
- AKBA 2007
- Country
- FIGS United States
- AKBA United States
- Employees
- FIGS N/A
- AKBA N/A
- Industry
- FIGS Apparel
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- AKBA Health Care
- Exchange
- FIGS Nasdaq
- AKBA Nasdaq
- Market Cap
- FIGS 694.0M
- AKBA 669.7M
- IPO Year
- FIGS 2021
- AKBA 2014
- Fundamental
- Price
- FIGS $4.36
- AKBA $3.03
- Analyst Decision
- FIGS Sell
- AKBA Strong Buy
- Analyst Count
- FIGS 4
- AKBA 4
- Target Price
- FIGS $4.50
- AKBA $6.63
- AVG Volume (30 Days)
- FIGS 2.1M
- AKBA 5.0M
- Earning Date
- FIGS 05-08-2025
- AKBA 05-08-2025
- Dividend Yield
- FIGS N/A
- AKBA N/A
- EPS Growth
- FIGS N/A
- AKBA N/A
- EPS
- FIGS 0.01
- AKBA N/A
- Revenue
- FIGS $561,166,000.00
- AKBA $184,909,000.00
- Revenue This Year
- FIGS $0.65
- AKBA $21.58
- Revenue Next Year
- FIGS $3.26
- AKBA $47.69
- P/E Ratio
- FIGS $597.72
- AKBA N/A
- Revenue Growth
- FIGS 3.02
- AKBA N/A
- 52 Week Low
- FIGS $3.57
- AKBA $0.80
- 52 Week High
- FIGS $7.06
- AKBA $3.14
- Technical
- Relative Strength Index (RSI)
- FIGS 46.03
- AKBA 71.68
- Support Level
- FIGS $4.36
- AKBA $2.76
- Resistance Level
- FIGS $4.66
- AKBA $3.14
- Average True Range (ATR)
- FIGS 0.20
- AKBA 0.15
- MACD
- FIGS -0.04
- AKBA 0.02
- Stochastic Oscillator
- FIGS 6.01
- AKBA 86.08
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.